Assess whether a CMC change is a comparability or a new product (73fc6f)

Situation

Biosimilar analytical similarity report arrived with a CRL citing manufacturing, not efficacy for clinical-development physician. That is a Pharma & Life Sciences FDA Response and Labeling decision on a CMC change is in a company with a CMC site change mid-review.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose A CMC change is a comparability / A new product using biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Biosimilar analytical similarity report reads as A CMC change is a comparability once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to A new product after a CRL citing manufacturing, not efficacy; A CMC change is a comparability would over-claim this FDA Response and Labeling extract.
• A dual reading is still live in biosimilar analytical similarity report for clinical-development physician in a company with a CMC site change mid-review.
• Biosimilar analytical similarity report is missing the fact clinical-development physician needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

Analysis required

• Check whether biosimilar analytical similarity report supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMC change is for clinical-development physician.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for clinical-development physician in a company with a CMC site change mid-review.